Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betazole SCHEMBL3336050 | 1.00 | HRH2 (1.00) | — | |
| Betazole SCHEMBL1237745 | 0.98 | — | — | |
| Betazole SCHEMBL1649674 | 0.98 | HRH2 (0.95) | — | |
| Betazole SCHEMBL29633745 | 0.98 | HRH2 (0.95) | — | |
| SCHEMBL4711257 | 0.86 | — | — | |
| Betazole SCHEMBL3336046 | 0.82 | USP2 (0.68) | — | |
| SCHEMBL2183872 | 0.80 | — | — | |
| SCHEMBL4222977 | 0.76 | — | — | |
| SCHEMBL21721708 | 0.76 | — | — | |
| Bromide SCHEMBL10400923 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 797 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148852-A1 | ORGANIC MOLECULE EXPOSOMICS | LINUS BIOTECHNOLOGY INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4673725-A2 | ORGANIC MOLECULE EXPOSOMICS | Linus Biotechnology Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12295388-B2 | Methods of modulating gastrointestinal metabolites | DSM IP ASSETS B.V. (NL) | 2025-05-13 | — | — | US | claimed |
| US-20240398819-A1 | UTILITY OF VITAMIN D, FOLIC ACID AND NADH TO IMPROVE LIGAMENT INJURY PREVENTION CHARACTERISTICS | RHODE ISLAND HOSPITAL | 2024-12-05 | — | — | US | claimed |
| WO-2024229174-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2024182308-A2 | ORGANIC MOLECULE EXPOSOMICS | LINUS BIOTECHNOLOGY INC. (US) | 2024-09-06 | — | — | WO | claimed |
| US-20220125074-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS B.V. (NL) | 2022-04-28 | — | — | US | claimed |
| EP-3876747-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP Assets B.V. (NL) | 2021-09-15 | — | — | EP | claimed |
| WO-2000010600-A9 | ACTIVATION AND PROTECTION OF T-CELLS (CD4+ AND CD8+) USING AN H¿2? RECEPTOR AGONIST AND OTHER T-CELL ACTIVATING AGENTS | MAXIM PHARM INC (US) | 2001-11-22 | — | — | WO | claimed |
| US-6305380-B1 | ADMINISTERING HISTAMINE AGONIST OR HT3 RECEPTOR ANTAGONIST TO ACTIVATE NATURAL KILLER CELLS AND TREAT VIRAL DISEASES | MAXIM PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | claimed |
| EP-1107784-A2 | ACTIVATION AND PROTECTION OF T-CELLS (CD4?+ AND CD8?+ ) USING AN H 2? RECEPTOR AGONIST AND OTHER T-CELL ACTIVATING AGENTS | Maxim Pharmaceuticals, Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| WO-2001006756-A2 | USE OF DIPHENYLIODONIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC LYMPHOCYTES | MAXIM PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | claimed |
| EP-0652768-B1 | A pharmaceutical preparation for the synergistic activation of natural killer cells | MAXIM PHARM INC (US) | 2000-05-03 | — | — | EP | claimed |
| WO-2000010600-A2 | ACTIVATION AND PROTECTION OF T-CELLS (CD4+ AND CD8+) USING AN H¿2? RECEPTOR AGONIST AND OTHER T-CELL ACTIVATING AGENTS | MAXIM PHARMACEUTICALS, INC. (US) | 2000-03-02 | — | — | WO | claimed |
| US-5728378-A | ANTITUMOR AND ANTIVIRUS AGENTS | MAXIM PHARMACEUTICALS, INC. (US) | 1998-03-17 | — | — | US | claimed |
| EP-0652768-A1 | PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-ALPHA AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY | MAXIM PHARMACEUTICALS, INC. (US) | 1995-05-17 | — | — | EP | claimed |
| WO-1993024144-A1 | PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY | SYNTELLO INC. (US) | 1993-12-09 | — | — | WO | claimed |
| US-4548805-A | Non-invasive test for gastric acid | SACK DAVID A | 1985-10-22 | — | — | US | claimed |